Generic Coreg CR Availability

See also: Generic Coreg

Coreg CR is a brand name of carvedilol, approved by the FDA in the following formulation(s):

COREG CR (carvedilol phosphate - capsule, extended release;oral)

• Manufacturer: SMITHKLINE BEECHAM
  Approval date: October 20, 2006
  Strength(s): 10MG, 20MG, 40MG ^[RLD], 80MG

Has a generic version of Coreg CR been approved?

No. There is currently no therapeutically equivalent version of Coreg CR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Coreg CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
  Patent 7,268,156
  Issued: September 11, 2007
  Inventor(s): Brook; Christopher S. & Chen; Wei & Spoors; Paul G.
  Assignee(s): SB Pharmco Puerto Rico Inc.
  The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
  
  Patent expiration dates:
  • June 27, 2023
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • June 27, 2023
    
    ✓ 
    Patent use: TREATMENT OF CONGESTIVE HEART FAILURE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • December 27, 2023
    
    ✓ 
    Pediatric exclusivity
• Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
  Patent 8,101,209
  Issued: January 24, 2012
  Inventor(s): Legrand; Valérie & Castan; Catherine & Meyrueix; Rémi & Soula; Gérard
  Assignee(s): Flamel Technologies
  The invention relates to a microparticulate system for the delayed and controlled release of active principles (AP) whose absorption window in vivo is essentially limited to the upper parts of the gastrointestinal tract, this system being intended for oral administration. The object of the invention is to provide a system ensuring that the AP is released with certainty by means of a dual mechanism of “time-dependent” and “pH-dependent” release. To achieve this object, the invention proposes a multimicrocapsular oral galenical form which is designed so as to guarantee therapeutic efficacy, and in which the release of the AP is governed by a dual release triggering mechanism that is “time-triggering” and “pH-triggering”. This system comprises of microcapsules (200 to 600 μm) comprising a core of AP coated with a film (maximum 40% by weight) comprising a hydrophilic polymer A (Eudragit® L) and a hydrophobic compound B (vegetable wax, melting point=40-90° C.), B/A being between 0.2 and 1.5. These microcapsules have a dissolution behavior in vitro such that, at a constant pH of 1.4, a latency phase of between 1 and 5 hours is observed, followed by a release of the AP, and such that the change from pH 1.4 to pH 6.8 results in a release of the AP without a latency period in vitro.
  
  Patent expiration dates:
  • September 11, 2025
    
    ✓ 
    Drug product
  • March 11, 2026
    
    ✓ 
    Pediatric exclusivity